Company news
XBiotech Inc. news in 2022
XBiotech Inc.'s news releases, calls and decks from 2022, newest first.
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
October 12, 2022
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study
June 19, 2022
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer
April 27, 2022
XBiotech Inks Clinical Manufacturing Deal
February 1, 2022
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ
January 25, 2022